Engage Bio
Durable genetic medicine, redosable
Santa Clara, California, US
A biotech startup developing mRNA immunotherapies to eliminate cancer. Their Tethosomes platform uses LNP technology to deliver DNA/mRNA, turning cancer cells into localized immunotherapy factories.
How We Help
Problem Statement
Delivering potent, durable, and scalable genetic medicine for solid tumors with minimized toxicity and immune evasion.
Core Technology
Tethosomes
Key Differentiators
Tethosomes platform turns cancer cells into immunotherapy factories; Localizes DNA to the nucleus for increased expression while evading immune sensors; A new class of non-viral DNA medicine for localized treatment
Clinical Focus
Oncology
Company Info
- Business Model
- Hybrid
- Total Funding
- 3,900,000
- Website
- engage.bio
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Platform advancing toward first human clinical programs. Gates Foundation grant awarded for non-viral DNA delivery technology. Y Combinator-backed (2022 seed: $500K).
MedStartr Index Score
?What do you think of Engage Bio?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.